Results 81 to 90 of about 19,009 (196)

Real‐World Survival Outcomes of Venetoclax Combination Therapies in Acute Myeloid Leukemia: Impact of Minimal Residual Disease Status and Antifungal Prophylaxis

open access: yesHematological Oncology, Volume 44, Issue 6, November 2026.
ABSTRACT In recent years the addition of the oral BCL2 inhibitor venetoclax to hypomethylating agents (HMAs) has emerged as the standard‐of‐care for patients with acute myeloid leukemia (AML) who are not fit for intensive chemotherapy, significantly improving survival and quality‐of‐life.
Mariarita Sciumè   +9 more
wiley   +1 more source

PRAME Augments K63‐Linked Ubiquitination and Stabilization of METTL3 to Promote Lung Adenocarcinoma Metastasis

open access: yesMedComm, Volume 7, Issue 11, November 2026.
PRAME promotes lung adenocarcinoma metastasis by inducing K63‐linked ubiquitination of METTL3 at lysine 235, thereby enhancing METTL3 stability and m6A methyltransferase complex assembly. Elevated METTL3 activity increases m6A modification of TGFB2 mRNA, leading to activation of TGF‐β signaling and metastatic progression of lung adenocarcinoma (LUAD ...
Xia Yang   +21 more
wiley   +1 more source

The nucleotidohydrolases DCTPP1 and dUTPase are involved in the cellular response to decitabine [PDF]

open access: yes, 2016
Decitabine (5-aza-2acute;-deoxycytidine, aza-dCyd) is an anticancer drug used clinically for the treatment of myelodysplastic syndromes and acute myeloid leukemia that can act as a DNA-demethylating or genotoxic agent in a dose-dependent manner.
Perez-Moreno, G.   +14 more
core   +1 more source

Comparison of maintenance with decitabine or chemotherapy in a real-world cohort of patients with acute myeloid leukemia

open access: yesFrontiers in Pharmacology
BackgroundThe objective of this real-world cohort study was to evaluate the efficacy and safety of decitabine versus conventional chemotherapy in the maintenance therapy (MT) of patients with acute myeloid leukemia (AML).MethodsData were collected from ...
Zhi-Feng Wei   +15 more
doaj   +1 more source

A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy

open access: yesHaematologica, 2012
Background The treatment of acute myeloid leukemia of older, medically non-fit patients still poses a highly unmet clinical need, and only few large, prospective studies have been performed in this setting.
Michael Lübbert   +18 more
doaj   +1 more source

The role of the adenosinergic pathway in resistance to hypomethylating agents in patients with high‐risk myelodysplastic syndromes

open access: yes
British Journal of Haematology, EarlyView.
George Vrachiolias   +15 more
wiley   +1 more source

Neutrophils: Heterogeneity, Biology, Diseases, and Therapeutic Strategies

open access: yesMedComm, Volume 7, Issue 11, November 2026.
Neutrophils exhibit remarkable functional plasticity and play dual roles in tissue protection and disease progression. This review summarizes their key biological functions and highlights the shift from conventional broad‐spectrum interventions to neutrophil‐based drug delivery systems.
Yibing Zhang   +4 more
wiley   +1 more source

Sequential decitabine and carboplatin treatment increases the DNA repair protein XPC, increases apoptosis and decreases proliferation in melanoma

open access: yesBMC Cancer, 2018
Background Melanoma has two key features, an over-representation of UV-induced mutations and resistance to DNA damaging chemotherapy agents. Both of these features may result from dysfunction of the nucleotide excision repair pathway, in particular the ...
Timothy Budden   +2 more
doaj   +1 more source

From infusion to pills in acute myeloid leukaemia: Reorganizing care beyond the infusion unit

open access: yes
British Journal of Haematology, EarlyView.
Fortunato Morabito   +11 more
wiley   +1 more source

Histone deacetylase inhibitors as venetoclax‐sensitising partners in acute myeloid leukaemia: Mechanisms, pharmacology and translational perspectives

open access: yesBritish Journal of Pharmacology, Volume 183, Issue 21, Page 6261-6290, November 2026.
Abstract Venetoclax combined with hypomethylating agents has improved treatment for older or unfit patients with acute myeloid leukaemia (AML), but resistance and relapse remain common. This review analyses the rationale for combining venetoclax with inhibitors of histone deacetylase (HDAC).
Jaebok Lee, Marc Diederich
wiley   +1 more source

Home - About - Disclaimer - Privacy